The firm trimmed the price target to $67 from $68 for the data and information holding company, and reduced the annual EPS estimate for fiscal 2015 to $2.64 from $2.68.
Deutsche Bank said it lowered Verisk Analytics' rating because market growth is expected to slow, putting emphasis on market share gains, and premium growth has decelerated to flat.
Must Read: Warren Buffett's 25 Favorite Stocks
"Total US Medicare Advantage (MA) enrollment growth is expected to slow into '15, making share gains more important to VRSK's largest Healthcare segment; insurance industry premium growth has decelerated to flat [year over year], which could drive slightly slower insurance rev growth in 2015; and we think any share price outperformance will come only from earnings beats and not multiple expansion," said Deutsche Bank analyst Paul Ginocchio.
Separately, TheStreet Ratings team rates VERISK ANALYTICS INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate VERISK ANALYTICS INC (VRSK) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, increase in stock price during the past year and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow."